- STADA had a good start to the year
- Both generics and branded products contribute to higher adjusted Group sales
- Significant margin improvement in both segments
- Transformation programme has already yielded positive results through cost savings in purchase and efficiencies in administration
- Double-digit growth of net income
- Increase in cash flow and improvement in net working capital
STADA key figures: Group
| | Q1/2018 | Q1/2017 | +/- |
| Reported Group sales |
EUR558.1 million |
EUR566.3 million |
-1% |
| Adjusted Group sales | EUR573.4 million | EUR552.0 million | +4% |
| Reported EBITDA |
EUR118.6 million |
EUR108.6 million |
+9% |
| Adjusted EBITDA | EUR118.4 million | EUR108.5 million | +9% |
| Reported net income |
EUR56.7 million |
EUR49.2 million |
+15% |
| Adjusted net income | EUR60.9 million | EUR53.3 million | +14% |
| Reported earnings per share |
EUR0.91 |
EUR0.79 |
+15% |
| Adjusted earnings per share | EUR0.98 | EUR0.86 | +14% |
According to Dr. Claudio Albrecht, CEO: "We got off to a good start in financial year 2018. The substantial improvements in profitability in both the Generics and Branded Products segments and the marked increase in net income show that the measures implemented in the transformation process are paying off. Overall, we are on track to meet the growth targets we have set for 2018."
Slight decrease in reported Group sales - increase in adjusted Group sales
In the reporting period, reported Group sales declined by 1 percent to EUR558.1 million. Sales generated by STADA Vietnam J.V. Co. Ltd. were no longer included. Group sales adjusted for portfolio and currency effects increased by 4 percent to EUR573.4?million. Both segments contributed to this growth.
Marked increase in both reported and adjusted EBITDA
Reported EBITDA increased by 9 percent to EUR118.6 million in the first quarter of 2018. Adjusted EBITDA grew by 9 percent to EUR118.4?million.
Significant increase in both reported and adjusted net income
Reported net income increased by 15 percent to EUR56.7 million in the reporting period. Adjusted net income grew by 14 percent to EUR60.9 million.
Increase in cash flow - improvement in net working capital
Cash flow from operating activities improved to EUR80.6 million in the first three months of 2018 (1-3/2017: EUR59.5 million). Free cash flow increased to EUR51.9 million (1-3/2017: EUR25.8 million). Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals increased to EUR61.5 million (1-3/2017: EUR39.7 million). Net working capital improved from EUR678.8 million as of December 31, 2017, to EUR649.9 million as of March 31, 2018.
Reduction in net debt
As of March 31, 2018, net debt was reduced to EUR1,006.5 million (December 31, 2017: EUR1,054.7 million). The net debt to adjusted EBITDA ratio (LTM; before on a full-year basis/on linear extrapolation) improved in the first quarter of 2018 to 2.3 (1-3/2017: 2.6) including the funding provided by Nidda Healthcare Holding GmbH.
STADA key figures: Generics segment
| | Q1/2018 | Q1/2017 | +/- |
| Reported sales |
EUR326.8 million |
EUR325.9 million |
0% |
| Adjusted sales | EUR332.8 million | EUR319.0 million | +4% |
| Adjusted EBITDA | EUR82.3 million | EUR69.4 million | +19% |
| Adjusted EBITDA margin | 25.2% | 21.3% | |
Sales development: Generics
Reported sales in the Generics segment in the first quarter of 2018 were more or less on a par with the previous-year quarter at EUR326.8 million. Sales generated by STADA Vietnam J.V. Co. Ltd. were no longer included.
Sales adjusted for portfolio and currency effects grew by 4 percent to EUR332.8 million.
Overall, the Generics segment accounted for 58.6 percent of Group sales (1-3/2017: 57.5 percent).
EBITDA and margin development: Generics
Adjusted EBITDA in the Generics segment increased by 19 percent to EUR82.3 million in the first three months of 2018.
The adjusted EBITDA margin was 25.2 percent (1-3/2017: 21.3 percent).
STADA key figures: Branded Products segment
| | Q1/2018 | Q1/2017 | +/- |
| Reported sales |
EUR231.3 million |
EUR240.4 million |
-4% |
| Adjusted sales | EUR240.6 million | EUR233.0 million | +3% |
| Adjusted EBITDA | EUR63.1 million | EUR57.0 million | +11% |
| Adjusted EBITDA margin | 27.3% | 23.7% | |
Sales development: Branded Products
Reported sales in the Branded Products segment declined by 4 percent to EUR231.3 million in the first quarter of 2018.
Sales adjusted for portfolio and currency effects grew by 3 percent to EUR240.6 million.
Overall, the Branded Products segment accounted for 41.4 percent of Group sales
(1-3/2017: 42.5 percent).
EBITDA and margin development: Branded Products
Adjusted EBITDA in the Branded Products segment increased by 11 percent to EUR63.1 million in the first three months of 2018.
The adjusted EBITDA margin in the Branded Products segment was 27.3 percent
(1-3/2017: 23.7 percent).
STADA reconciliation of special items in the first quarter of 2018
| (EUR million1) | Reported first quarter of 2018 |
Impairment/write-ups on non-current assets |
Effects from purchase price allocations and product acquisitions2 | Adjusted first quarter of 2018 |
| Earnings before interest, taxes, depreciation and amortization (EBITDA) | 118.6 |
-- |
-0.2 | 118.4 |
| Balance from depreciation/amortization and impairment/write-ups for intangible assets (including goodwill), property, plant and equipment and financial assets | 30.4 |
-1.8 |
-3.3 | 25.3 |
| Financial income and expenses | -8.1 |
-- |
-- | -8.1 |
| Income taxes | 22.4 |
0.5 |
0.4 | 23.3 |
| Result attributable to non-controlling shareholders | 1.0 |
-- |
-0.1 | 0.9 |
| Result attributable to the shareholders of STADA Arzneimittel AG (net income) | 56.7 |
1.3 |
2.9 | 60.9 |
1 Due to the presentation in EUR million, deviations may appear in the tables due to rounding.
2 Concerns additional depreciation/amortization and other valuation effects due to purchase price allocations and significant product
acquisitions compared with the 2013 financial year as the base level.
Contact:
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel - Germany Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de
Or visit us in the Internet at www.stada.com.
03.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
STADA ARZNEIMITTEL 
